BioCryst Pharmaceuticals, Inc. (BCRX) vs Pacira BioSciences, Inc. (PCRX)
- BioCryst Pharmaceuticals, Inc. BCRX 7.79 −2.87%
- Pacira BioSciences, Inc. PCRX 36.35 +0.06%
BioCryst Pharmaceuticals, Inc. and Pacira BioSciences, Inc. are both Drug Manufacturers Specialty & Generic companies. BioCryst Pharmaceuticals, Inc. is the larger, with a market value of $2.1B against $1.5B — 1.4× the size. BioCryst Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Pacira BioSciences, Inc. trades at 104×. BioCryst Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 68.7% against 5.71%. Pacira BioSciences, Inc. has the higher net margin (1.96% vs −40.9%) and the higher return on invested capital (1.58% vs −610.6%). Across the 19 metrics below, BioCryst Pharmaceuticals, Inc. leads on 11 and Pacira BioSciences, Inc. on 8.
Valuation
Profitability
| Metric | BCRX | PCRX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.78% | 79.21% | 53.94% |
| Operating margin | (33.29%) | 2.66% | 0.00% |
| Net margin | (40.90%) | 1.96% | 0.00% |
| Free cash flow margin | 39.75% | 24.06% | 0.00% |
| Return on equity | 87.84% | 2.05% | (0.40%) |
| Return on assets | (75.79%) | 1.05% | (3.32%) |
| Return on invested capital | (610.55%) | 1.58% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack